Status:
WITHDRAWN
Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).
Lead Sponsor:
Johann Wolfgang Goethe University Hospital
Conditions:
SDF-1 is an Important Cytokine for Neovascularization. Cleavage of SDF-1 is Reduced by DPPIV Inhibitors
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
PHASE3
Brief Summary
SDF-1, an important cytokine for neovascularisation is cleaved by (dipeptidyl peptidase IV) DPPIV. The aim of this study is to assess the effect of the dipeptidyl peptidase IV inhibitor vildagliptin ...
Detailed Description
The peptidase CD26 (DPPIV/dipeptidyl peptidase IV) removes dipeptides from the amino terminus of proteins and thereby inactivates these cleaved proteins. It was shown, that CD26 cleaves SDF-1 into a n...
Eligibility Criteria
Inclusion
- Patients with diabetes mellitus type 2 under stable medication
- HbA1c between 7% an 10%
- age between 18 and 80 years
- signed informed consent
Exclusion
- Atrial fibrillation (plethysmographic recordings can only obtained in sinus-rhythm)
- CAD with reduced left ventricular ejection fraction (LVEF \<45%)
- Pregnancy, chronic or acute infection, fever
- Diabetes mellitus type 1
- Newly diagnosed diabetes, uncontrolled diabetes
- Neoplasm
- Known allergy to study drug
- Severe liver/kidney disease
- HIV, Hepatitis
- Participation at other studies within the last 30 days
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2013
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00936234
Start Date
July 1 2009
End Date
May 1 2013
Last Update
September 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Cardiology
Frankfurt, Germany, 60590